Document ID: chunk:federal_register_of_legislation:F2023L00940:reg:9:p4
Version: federal_register_of_legislation:F2023L00940
Segment Type: reg
Provision Reference: reg 9 (pt 4/6)
Character Range: 12737–15792

failure is defined in the Schedule 1 – Dictionary.
(35)      having sarcoidosis at the time of the clinical worsening of peripheral neuropathy;
(36)      having an endocrine disease from the specified list of endocrine diseases at the time of the clinical worsening of peripheral neuropathy;
Note: specified list of endocrine diseases is defined in the Schedule 1 – Dictionary.
(37)      having an autoimmune disease from the specified list of autoimmune diseases at the time of the clinical worsening of peripheral neuropathy;
Note: specified list of autoimmune diseases is defined in the Schedule 1 – Dictionary.
(38)      having a systemic vasculitis from the specified list of forms of systemic vasculitis at the time of the clinical worsening of peripheral neuropathy;
Note: specified list of forms of systemic vasculitis is defined in the Schedule 1 – Dictionary.
(39)      having a haematological or lymphoproliferative disorder from the specified list of haematological or lymphoproliferative disorders at the time of the clinical worsening of peripheral neuropathy;
Note: specified list of haematological or lymphoproliferative disorders is defined in the Schedule 1 – Dictionary.
(40)      having a malignant neoplasm, other than non-melanotic malignant neoplasm of the skin, at the time of the clinical worsening of peripheral neuropathy;
(41)      having a neurological paraneoplastic syndrome at the time of the clinical worsening of peripheral neuropathy;
(42)      having a critical illness within the 30 days before the clinical worsening of peripheral neuropathy;
Note: critical illness is defined in the Schedule 1 – Dictionary.
(43)      having severe alcohol use disorder at the time of the clinical worsening of peripheral neuropathy;
Note: severe alcohol use disorder is defined in the Schedule 1 – Dictionary.
(44)      consuming at least 200 kilograms of alcohol within the 10 years before the clinical worsening of peripheral neuropathy;
Note: Alcohol consumption is calculated utilising the Australian Standard of 10 grams of alcohol per standard alcoholic drink.
(45)      inhaling, ingesting or having cutaneous contact with a chemical from the specified list of chemicals (short term exposure);
(a)          on at least 30 occasions within a continuous period of 6 months before the clinical worsening of peripheral neuropathy; and
(b)          where exposure has ceased before the clinical worsening of peripheral neuropathy, then that worsening occurred within 3 months of cessation;
Note: specified list of chemicals (short term exposure) is defined in the Schedule 1 – Dictionary.
(46)      inhaling, ingesting or having cutaneous contact with a chemical from the specified list of chemicals (long term exposure):
(a)          on more days than not for at least 1 year before the clinical worsening of peripheral neuropathy, and
(b)          where exposure has ceased before the clinical worsening of peripheral neuropathy, then that worsening occurred within 3 months of cessation;
Note: specified list of chemicals (long